2-Chloro-2′-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells

Tieran Han, Marilyn Fernandez, Ting Chao Chou, Ram P. Agarwal

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This report presents quantitative analysis of the synergistic interaction of azidothymidine (AZT) and cladribine (CdA) in human H9-lymphoid cell lines sensitive and resistant to AZT (H9-araC cells). H9-araC cells obtained by cultivation of H9 cells in the presence of 0.5μM arabinosyl-cytosine (araC) had lower deoxycytidine kinase and thymidine kinase (TK) activities and expressed cross-resistance to araC and AZT. The IC50 values of AZT and CdA were calculated by using median-effect analysis and CalcuSyn software. The IC50 values were 0.44 and 0.82μM for CdA and 67.8 and 30,310μM for AZT in H9 and H9-araC cells, respectively. However, when the drugs were used in combination the IC50 values of CdA and AZT were reduced to 0.12 and 15.5μM in H9 cells and to 0.19 and 24.9μM in H9-araC cells, respectively. Calculation of dose reduction index (DRI) indicated that at 50-90% growth inhibition level, the combination of the drugs caused 3.6-5.8- and 4.1-11.5-fold reduction in the dose of CdA and 4.4-37.6- and >1000-fold reduction in the dose of AZT in H9 and H9-araC cells, respectively. The combination index (CI) values simulated from these data suggested synergistic to very strong synergistic lymphocytotoxic effects of AZT combined with CdA. These findings suggest the potential usefulness of a double-targeted approach for designing efficacious therapeutics for the kinase deficient drug resistant tumors.

Original languageEnglish
Pages (from-to)518-522
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume316
Issue number2
DOIs
StatePublished - Apr 2 2004
Externally publishedYes

Fingerprint

Zidovudine
Cytotoxicity
Cytosine
Lymphocytes
Inhibitory Concentration 50
Deoxycytidine Kinase
Cladribine
Thymidine Kinase
2'-deoxyadenosine
Drug Combinations
Pharmaceutical Preparations
Tumors
Phosphotransferases
Software
Cells
Cell Line
Growth
Chemical analysis

Keywords

  • Azidothymidine
  • Cladribine
  • Effect of cladribine on azidothymidine activation
  • Synergistic cytotoxicity

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

2-Chloro-2′-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells. / Han, Tieran; Fernandez, Marilyn; Chou, Ting Chao; Agarwal, Ram P.

In: Biochemical and Biophysical Research Communications, Vol. 316, No. 2, 02.04.2004, p. 518-522.

Research output: Contribution to journalArticle

@article{98feb005558c45bdba9dab46fe480717,
title = "2-Chloro-2′-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells",
abstract = "This report presents quantitative analysis of the synergistic interaction of azidothymidine (AZT) and cladribine (CdA) in human H9-lymphoid cell lines sensitive and resistant to AZT (H9-araC cells). H9-araC cells obtained by cultivation of H9 cells in the presence of 0.5μM arabinosyl-cytosine (araC) had lower deoxycytidine kinase and thymidine kinase (TK) activities and expressed cross-resistance to araC and AZT. The IC50 values of AZT and CdA were calculated by using median-effect analysis and CalcuSyn software. The IC50 values were 0.44 and 0.82μM for CdA and 67.8 and 30,310μM for AZT in H9 and H9-araC cells, respectively. However, when the drugs were used in combination the IC50 values of CdA and AZT were reduced to 0.12 and 15.5μM in H9 cells and to 0.19 and 24.9μM in H9-araC cells, respectively. Calculation of dose reduction index (DRI) indicated that at 50-90{\%} growth inhibition level, the combination of the drugs caused 3.6-5.8- and 4.1-11.5-fold reduction in the dose of CdA and 4.4-37.6- and >1000-fold reduction in the dose of AZT in H9 and H9-araC cells, respectively. The combination index (CI) values simulated from these data suggested synergistic to very strong synergistic lymphocytotoxic effects of AZT combined with CdA. These findings suggest the potential usefulness of a double-targeted approach for designing efficacious therapeutics for the kinase deficient drug resistant tumors.",
keywords = "Azidothymidine, Cladribine, Effect of cladribine on azidothymidine activation, Synergistic cytotoxicity",
author = "Tieran Han and Marilyn Fernandez and Chou, {Ting Chao} and Agarwal, {Ram P.}",
year = "2004",
month = "4",
day = "2",
doi = "10.1016/j.bbrc.2004.02.085",
language = "English",
volume = "316",
pages = "518--522",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - 2-Chloro-2′-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells

AU - Han, Tieran

AU - Fernandez, Marilyn

AU - Chou, Ting Chao

AU - Agarwal, Ram P.

PY - 2004/4/2

Y1 - 2004/4/2

N2 - This report presents quantitative analysis of the synergistic interaction of azidothymidine (AZT) and cladribine (CdA) in human H9-lymphoid cell lines sensitive and resistant to AZT (H9-araC cells). H9-araC cells obtained by cultivation of H9 cells in the presence of 0.5μM arabinosyl-cytosine (araC) had lower deoxycytidine kinase and thymidine kinase (TK) activities and expressed cross-resistance to araC and AZT. The IC50 values of AZT and CdA were calculated by using median-effect analysis and CalcuSyn software. The IC50 values were 0.44 and 0.82μM for CdA and 67.8 and 30,310μM for AZT in H9 and H9-araC cells, respectively. However, when the drugs were used in combination the IC50 values of CdA and AZT were reduced to 0.12 and 15.5μM in H9 cells and to 0.19 and 24.9μM in H9-araC cells, respectively. Calculation of dose reduction index (DRI) indicated that at 50-90% growth inhibition level, the combination of the drugs caused 3.6-5.8- and 4.1-11.5-fold reduction in the dose of CdA and 4.4-37.6- and >1000-fold reduction in the dose of AZT in H9 and H9-araC cells, respectively. The combination index (CI) values simulated from these data suggested synergistic to very strong synergistic lymphocytotoxic effects of AZT combined with CdA. These findings suggest the potential usefulness of a double-targeted approach for designing efficacious therapeutics for the kinase deficient drug resistant tumors.

AB - This report presents quantitative analysis of the synergistic interaction of azidothymidine (AZT) and cladribine (CdA) in human H9-lymphoid cell lines sensitive and resistant to AZT (H9-araC cells). H9-araC cells obtained by cultivation of H9 cells in the presence of 0.5μM arabinosyl-cytosine (araC) had lower deoxycytidine kinase and thymidine kinase (TK) activities and expressed cross-resistance to araC and AZT. The IC50 values of AZT and CdA were calculated by using median-effect analysis and CalcuSyn software. The IC50 values were 0.44 and 0.82μM for CdA and 67.8 and 30,310μM for AZT in H9 and H9-araC cells, respectively. However, when the drugs were used in combination the IC50 values of CdA and AZT were reduced to 0.12 and 15.5μM in H9 cells and to 0.19 and 24.9μM in H9-araC cells, respectively. Calculation of dose reduction index (DRI) indicated that at 50-90% growth inhibition level, the combination of the drugs caused 3.6-5.8- and 4.1-11.5-fold reduction in the dose of CdA and 4.4-37.6- and >1000-fold reduction in the dose of AZT in H9 and H9-araC cells, respectively. The combination index (CI) values simulated from these data suggested synergistic to very strong synergistic lymphocytotoxic effects of AZT combined with CdA. These findings suggest the potential usefulness of a double-targeted approach for designing efficacious therapeutics for the kinase deficient drug resistant tumors.

KW - Azidothymidine

KW - Cladribine

KW - Effect of cladribine on azidothymidine activation

KW - Synergistic cytotoxicity

UR - http://www.scopus.com/inward/record.url?scp=1542635081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542635081&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2004.02.085

DO - 10.1016/j.bbrc.2004.02.085

M3 - Article

C2 - 15020247

AN - SCOPUS:1542635081

VL - 316

SP - 518

EP - 522

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -